ComplianceOnline

Quality Expectations for Product Development CMC Activities: R & D, GLP or GMP

Instructor: Steven S Kuwahara
Product ID: 700949
  • Duration: 75 Min

recorded version

$299.00
1x Person - Unlimited viewing for 6 Months
(For multiple locations contact Customer Care)
Recorded Link and Ref. material will be available in My CO Section

Training CD

$500.00
One CD is for usage in one location only.
(For multiple locations contact Customer Care)
CD and Ref. material will be shipped within 15 business days

Customer Care

Fax: +1-650-963-2556

Email: customercare@complianceonline.com

Read Frequently Asked Questions

This presentation will discuss the quality-related activities that are expected for different stages of the product development process.

Description

Emphasis will be placed on the transition into full GMP work as clinical trials proceed, but the requirements for DMFs and NDAs (or BLAs) will be discussed.

There are certain quality-related activities that are expected when information is gathered for the CMC section of an application. The nature and extent of these activities depend on the submission that is planned, and their variation is especially marked when considering submissions to perform experimental studies during the different phases of clinical trials. This presentation will discuss the quality-related activities that are expected for different stages of the product development process. Emphasis will be placed on the transition into full GMP work as clinical trials proceed, but the requirements for DMFs and NDAs (or BLAs) will be discussed. The quality elements for CMCs that are common to all types and stages of submissions will be discussed.

Areas Covered in the seminar:

  • Which regulations come into play at different stages of product development.
  • What to do at early stages.
  • Varying levels of GMP stringency.
  • Letting FDA help you in making your submission.
  • Use of the Common Technical Document (CTD) to determine activities.
  • FDA guidance documents that help to tell you what to do.
  • What to do about QC studies such as instrument qualification, method validation, and process validation.
  • What do you need for the CMC section?
  • What are the common elements?

Who will benefit:

This presentation will be aimed at helping Regulatory, Quality Assurance and Quality Control personnel to understand the varying levels of quality activities that accompany different stages of Product development.

  • Regulatory Affairs personnel who coordinated activities for the CMC sections of submissions.
  • QA/QC personnel who need to plan work.
  • R & D personnel who will contribute data to CMC sections.
  • Project managers for product development studies.
  • Quality systems auditors.
  • Consultants.

Instructor Profile

Steven S. Kuwahara, Ph.D. is the founder and Principal of GXP BioTechnology LLC, a consulting firm that works in the areas covered by the GLP and GMP of drugs, biologics, and nutraceuticals. Steve has over 30 years of experience in supervising quality control laboratories, including an animal testing facility, and in performing GLP and GMP audits of internal and external testing laboratories. He has participated in the product development process for small molecule drugs and biologics, and has prepared or reviewed many CMC sections.

Follow us :
ComplianceOnline Banking Summit 2016 | Risk Management and Data Security - 80390SEM
ComplianceOnline Medical Device Summit 2017

Product Reviews Write review

I really got a lot of good, practical information fromt this seminar. The speaker did not just read his presentation but provided meaningful explanations and examples. This is something you cannot get from purchasing a pre-prepared seminar or book. The speaker took the time to understand the questions and gave meaningful answers.
- Anonymous

Best Sellers
You Recently Viewed
    Loading